Phil Nadeau

Acorda’s Ampyra Improves Walking in Stroke Patients

Acorda Therapeutics Inc., maker of the drug Ampyra to improve walking in multiple sclerosis patients, rose to its highest value in more than two years after the company said a small study showed the medicine also helped people who have had strokes.

Amylin, Lilly, Alkermes Shares Fall on Bydureon Delay

Amylin Pharmaceuticals Inc. , Eli Lilly & Co. and Alkermes Inc . dropped in trading after they were rebuffed a second time in a bid to gain U.S. approval of a once- weekly version of the diabetes drug Byetta.

Sanofi Begins $18.5 Billion Hostile Offer for Genzyme

Sanofi-Aventis SA began an $18.5 billion hostile takeover offer for Genzyme Corp. after the U.S. biotechnology company spurned the bid as too low. Genzyme urged shareholders to take no immediate action.

Ariad Sinks on Safety Warnings With U.S. Drug Approval

Ariad Pharmaceuticals Inc., a developer of cancer drugs, sank the most in more than four years after the company’s cancer medicine received a warning label with U.S. approval to treat two rare types of leukemia.

Regeneron Shares Fall as Eylea Disappoints Investors

Regeneron Pharmaceuticals Inc., the drugmaker today celebrating the 25th anniversary of its incorporation, fell the most in five weeks after reporting sales for its eye drug Eylea that disappointed investors.

Regeneron Shares Advance on Sanofi’s Plan to Buy Stock

Regeneron Pharmaceuticals Inc., maker of the eye medicine Eylea, rose the most in three weeks on drug-development partner Sanofi’s plans to raise its stake in the company by buying shares on the stock market.

Orexigen Plunges as FDA Requests More Diet Pill Data

Orexigen Therapeutics Inc. plunged as much as 73 percent after U.S. regulators said the company must submit more data before its diet pill Contrave may be cleared for sale. Diet-drug developer Vivus Inc. also fell.

Vertex, J&J Hepatitis C Drug Works After Others Fail

Vertex Pharmaceuticals Inc .’s most advanced experimental drug, in development with Johnson & Johnson, worked in patients with hepatitis C who didn’t respond to other treatment, a study found.

Cravath, Weil, Kirkland, Skadden, Sullivan: Business of Law

Linde AG agreed to acquire Lincare Holdings Inc. for about $3.8 billion to add U.S. oxygen and respiratory therapy services delivered to the home, in the German company’s biggest acquisition since 2006.

Gene Therapy Revival Spurs Hope for Genzyme, Pfizer

Five years ago, doctors drilled a hole into Jean Erickson’s skull, pushed in a needle and injected a cold virus modified to help transport a gene into her brain.

New York

Food And Drug Administration

Asia

U.S. Stocks, Dollar Rise as Data Fuel Economic Confidence

U.S. Stocks Advance on Leading Indicators, Sentiment Data

Gold Heads for Longest Slump in Four Years on Fed, Dollar

‘Star Trek’ $112 Million Open to Put Summer in Warp Drive

Exiting IRS Chief Denies Targeting as Republicans Pounce